葛兰素史克Glaxosmithkline plc (GSK) 2022年年度报告「LSE」.pdf

1、Annual Report 2022GSK Annual Report 2022Strategic reportAhead Together 012022 performance and key performance indicators 02Chairs statement 04CEOs statement 06Business model 08Our culture and people 10Our external environment 12Research and development 15Commercial operations:Performance:Vaccines 29

2、Performance:Specialty Medicines 33Performance:General Medicines 38Responsible business 41 Risk management 512022 principal risks summary 53Climate-related financial disclosures 55Nature-related financial disclosure 62Employees by gender 63Viability statement 64Group financial review 65We are a globa

3、l biopharma company with a purpose to unite science,technology and talent to get ahead of disease together.We aim to positively impact the health of 2.5 billion people by the end of 2030.Our bold ambitions for patients are reflected in commitments to growth and a step-change in performance.We are a

4、company where outstanding people can thrive.Cautionary statementSee the inside back cover of this document for the cautionary statement regarding forward-looking statements.Non-IFRS measuresWe use a number of adjusted,non-International Financial Reporting Standards(IFRS)measures to report the perfor

5、mance of our business.Total reported results represent the Groups overall performance under IFRS.Adjusted results and other non-IFRS measures may be considered in addition to,but not as a substitute for or superior to,information presented in accordance with IFRS.Adjusted results and other non-IFRS

6、measures are defined on pages 69 and 70 and reconciliations to the nearest IFRS measures are on pages 81 to 85.Corporate governanceThe Board and GSK Leadership Team 97Chairs governance statement 103Corporate governance architecture 107Ahead Together Board oversight 110Key decisions and engagements 1